186 related articles for article (PubMed ID: 26210849)
21. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma.
Choi J; Park Y; Kim JH; Kim HS
Clin Biochem; 2011 Dec; 44(17-18):1464-8. PubMed ID: 21939644
[TBL] [Abstract][Full Text] [Related]
24. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
25. [Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma].
Yoon YJ; Han KH; Kim C; Chon CY; Moon YM; Han CH; Choi HJ; Kim YS; Han JY; Kim HS
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):465-71. PubMed ID: 12506251
[TBL] [Abstract][Full Text] [Related]
26. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
Sakizono K; Oita T; Kuroda M; Kasakura S
Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.
Kuromatsu R; Tanaka M; Shimauchi Y; Shimada M; Tanikawa K; Watanabe K; Yokoo T
J Gastroenterol; 1997 Aug; 32(4):507-12. PubMed ID: 9250899
[TBL] [Abstract][Full Text] [Related]
29. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
30. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
[TBL] [Abstract][Full Text] [Related]
31. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
Ryu MR; Kang ES; Park HD
J Clin Lab Anal; 2019 Jul; 33(6):e22921. PubMed ID: 31131509
[TBL] [Abstract][Full Text] [Related]
32. The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.
Kang KH; Kim JH; Kang SH; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Gut Liver; 2015 Mar; 9(2):224-30. PubMed ID: 25473073
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.
Park H; Park JY
Biomed Res Int; 2013; 2013():310427. PubMed ID: 24455683
[TBL] [Abstract][Full Text] [Related]
34. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
35. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
Motohara K; Endo F; Matsuda I; Iwamasa T
J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis.
Zhang D; Liu Z; Yin X; Qi X; Lu B; Liu Y; Hou J
Int J Biol Markers; 2018 Aug; 33(3):266-274. PubMed ID: 29658364
[TBL] [Abstract][Full Text] [Related]
37. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma.
Deyashiki Y; Nishioka Y; Takahashi K; Kosaka Y; Suzuki K
Cancer; 1989 Dec; 64(12):2546-51. PubMed ID: 2555040
[TBL] [Abstract][Full Text] [Related]
39. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
40. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
